Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers.
about
Levosimendan: current data, clinical use and future developmentAdvanced heart failure: an appraisal of the potential of levosimendan in this end-stage scenario and some related ethical considerations.Effects of a myofilament calcium sensitizer on left ventricular systolic and diastolic function in rats with volume overload heart failureThe effects of levosimendan and dobutamine in experimental bupivacaine-induced cardiotoxicity.Retraction. rhBNP therapy can improve clinical outcomes and reduce in-hospital mortality compared with dobutamine in heart failure patients: a meta-analysis.Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials.Preoperative usages of levosimendan in patients undergoing coronary artery bypass grafting.Pharmacological treatment of acute heart failure: current treatment and new targets.Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis.Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses.Dobutamine Therapy is Associated with Worse Clinical Outcomes Compared with Nesiritide Therapy for Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis.Update on the Management of Acute Decompensated Heart Failure.A single German center experience with intermittent inotropes for patients on the high-urgent heart transplant waiting list.Levosimendan for patients with severely reduced left ventricular systolic function and/or low cardiac output syndrome undergoing cardiac surgery: a systematic review and meta-analysis.How to treat acute decompensated heart failure in the 'beta-blocker era'?Correspondence concerning the article: is levosimendan better than dobutamine in acute heart failure in patients on beta blockade treatment? What is the evidence?Is levosimendan better than dobutamine in acute heart failure in patients on beta-blockade treatment? What is the evidence?Levosimendan improves renal function in acute decompensated heart failure: possible underlying mechanisms.The inodilator levosimendan in repetitive doses in the treatment of advanced heart failure.The clinical effects of levosimendan are not attenuated by sulfonylureas.Scandinavian SSAI clinical practice guideline on choice of inotropic agent for patients with acute circulatory failure.
P2860
Q24629274-12CCD413-77CE-4510-B6F7-3FC193772EC7Q30394479-7DE093DE-1719-477A-A0D1-ACF6AD0729BCQ34627826-049D44C4-4F42-4569-BF2C-051A9FF353EEQ35006812-05C01F48-39AE-40AA-B962-938854D2E16BQ36410248-968563C2-C38A-4D21-A7B6-FB638B13D191Q36832816-251AF3F2-4BDB-49D3-9947-38CFF559036FQ37516407-2FFA1046-A8C2-41FB-A6BE-48442018B235Q38122297-4428CA10-2244-4A5F-B06A-F3593121A93AQ38292123-30276890-A3DC-411A-9CF4-4177DAD89D0DQ38500442-274ABBD0-6334-4CA7-8B0F-C0FAA9388761Q38540286-3467BAA2-4241-457D-8E90-CE2905378BD8Q39258163-541311E8-4FC3-4919-8A79-54031FD31B78Q41115730-1FB3E65F-0C8E-456E-9F46-AEC1EB180B5FQ42672323-F1355A24-C6AD-4F5A-8F86-4AD433AB6DC9Q42950220-BED4D325-8D29-4043-B5FE-E0497356EB92Q42950223-750FB626-BA24-48EB-AEDC-5C0BCBEB209DQ43119695-ADFB0911-B35D-4845-9B3D-D6C3CE2A4603Q45742045-579ECFB1-1015-47B0-8D8A-4597591CEC55Q47156435-DEC53B45-DA9D-4208-AB63-5BF5D202CB8FQ47212291-7EA77240-CE18-4F20-9070-41516DA26C82Q55041662-1D92FDCC-453B-4844-B636-42B95FF52A3A
P2860
Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Intravenous levosimendan vs. d ...... ure patients on beta-blockers.
@ast
Intravenous levosimendan vs. d ...... ure patients on beta-blockers.
@en
type
label
Intravenous levosimendan vs. d ...... ure patients on beta-blockers.
@ast
Intravenous levosimendan vs. d ...... ure patients on beta-blockers.
@en
prefLabel
Intravenous levosimendan vs. d ...... ure patients on beta-blockers.
@ast
Intravenous levosimendan vs. d ...... ure patients on beta-blockers.
@en
P2093
P2860
P356
P1476
Intravenous levosimendan vs. d ...... ure patients on beta-blockers.
@en
P2093
Bengt Ullman
Bert Andersson
Claes-Håkan Bergh
Gerhard Wikström
Kolbjorn Forfang
Matti Kivikko
Toni Sarapohja
Ulf Dahlström
P2860
P304
P356
10.1093/EURJHF/HFQ032
P577
2010-04-01T00:00:00Z